Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Provigil Sleep Apnea Studies To Finish in 2000, Will Be First sNDA Filed - CEO

Executive Summary

Clinical data from Cephalon's Provigil trials in sleep apnea patients will be available in early 2000, with a supplemental NDA filing to be discussed after that, Cephalon CEO Frank Baldino, PhD, said Jan. 13 at the Hambrecht & Quist conference in San Francisco.
Advertisement

Related Content

Cephalon Provigil Reformulation Will Be Filed With FDA By Year-End
Cephalon Provigil Reformulation Will Be Filed With FDA By Year-End
Advertisement
UsernamePublicRestriction

Register

PS033490

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel